{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:46:38Z","timestamp":1790696798925,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Cocaine is a highly addictive substance, and with no approved medication for cocaine use disorder (CUD), leading to a heavy burden. Despite validated psychosocial treatments, relapse rates after detoxification are very high in CUD. Few consistent factors can predict abstinence after detoxification. Our study, therefore, aimed at identifying factors predicting abstinence among CUD patients after inpatient detoxification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty\u2010one CUD inpatients were included during detoxification and characterized for clinical and sociodemographic data at baseline and at a follow\u2010up of 3 months after discharge, including a standard measure of their abstinence duration from cocaine. We performed Cox univariate analyzes to determine the factors associated with abstinence maintenance, followed by a multivariate Cox regression to identify independent predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Abstinence maintenance was shorter in patients injecting cocaine (hazard ratio [HR]\u2009=\u20095.16, 95% confidence interval [CI]: 2.01\u201313.27,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001) and using cocaine heavily in the month before inclusion (HR\u2009=\u20091.03, 95% CI: 1.00\u20131.06,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.046). Conversely, abstinence maintenance was longer in patients with longer inpatient detoxification stays (HR\u2009=\u20090.96, 95% CI: 0.94\u20130.99,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.015) and prescribed with selective serotonin reuptake inhibitors (SSRIs) (HR\u2009=\u20090.30, 95% CI: 0.16\u20130.56,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and Conclusions<\/jats:title>\n                    <jats:p>Patients with severe CUD may require longer inpatient stays to achieve abstinence. Regarding SSRI prescription, more specific studies are needed to provide stronger recommendations about their use in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Scientific Significance<\/jats:title>\n                    <jats:p>Our findings suggest several modifiable factors to improve inpatient treatment response in CUD. As there are no specific recommendations about the optimal duration of inpatient stay, our results could pave the way for evidence\u2010based guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajad.13571","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T08:09:57Z","timestamp":1716019797000},"page":"576-582","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Predictors of abstinence maintenance after cocaine inpatient detoxification: A prospective study"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-4289","authenticated-orcid":false,"given":"Margaux","family":"Poireau","sequence":"first","affiliation":[{"name":"D\u00e9partement de Psychiatrie et de M\u00e9decine Addictologique H\u00f4pital Fernand Widal, APHP Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 UMR\u2010S 1144 Therapeutic Optimization in Neuropsychopharmacology INSERM Paris France"},{"name":"FHU NOR\u2010SUD (Network of Research in Substance Use Disorders) APHP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-8249","authenticated-orcid":false,"given":"Virgile","family":"Clergue\u2010Duval","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Psychiatrie et de M\u00e9decine Addictologique H\u00f4pital Fernand Widal, APHP Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 UMR\u2010S 1144 Therapeutic Optimization in Neuropsychopharmacology INSERM Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9line","family":"Maillard","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Psychiatrie et de M\u00e9decine Addictologique H\u00f4pital Fernand Widal, APHP Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 UMR\u2010S 1144 Therapeutic Optimization in Neuropsychopharmacology INSERM Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5078-4048","authenticated-orcid":false,"given":"Romain","family":"Icick","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Psychiatrie et de M\u00e9decine Addictologique H\u00f4pital Fernand Widal, APHP Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 UMR\u2010S 1144 Therapeutic Optimization in Neuropsychopharmacology INSERM Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Azuar","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Psychiatrie et de M\u00e9decine Addictologique H\u00f4pital Fernand Widal, APHP Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 UMR\u2010S 1144 Therapeutic Optimization in Neuropsychopharmacology INSERM Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Smith","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Psychiatrie et de M\u00e9decine Addictologique H\u00f4pital Fernand Widal, APHP Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 UMR\u2010S 1144 Therapeutic Optimization in Neuropsychopharmacology INSERM Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Faurent","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Psychiatrie et de M\u00e9decine Addictologique H\u00f4pital Fernand Widal, APHP Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 UMR\u2010S 1144 Therapeutic Optimization in Neuropsychopharmacology INSERM Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Volle","sequence":"additional","affiliation":[{"name":"FRONT\u2010Lab ICM Institut du Cerveau INSERM Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Delmaire","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 UMR\u2010S 1144 Therapeutic Optimization in Neuropsychopharmacology INSERM Paris France"},{"name":"Service de Neuroradiologie Fondation Ophtalmologique Rothschild Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Cab\u00e9","sequence":"additional","affiliation":[{"name":"Clermont Auvergne INP CHU Clermont\u2010Ferrand CNRS Institut Pascal Universit\u00e9 Clermont Auvergne Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Bloch","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 UMR\u2010S 1144 Therapeutic Optimization in Neuropsychopharmacology INSERM Paris France"},{"name":"FHU NOR\u2010SUD (Network of Research in Substance Use Disorders) APHP Paris France"},{"name":"Service de Pharmacie \u00e0 Usage Interne H\u00f4pital Fernand Widal, APHP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Vorspan","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Psychiatrie et de M\u00e9decine Addictologique H\u00f4pital Fernand Widal, APHP Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9 UMR\u2010S 1144 Therapeutic Optimization in Neuropsychopharmacology INSERM Paris France"},{"name":"FHU NOR\u2010SUD (Network of Research in Substance Use Disorders) APHP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"UNODC. World Drug Report 2022. Published online2022."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00367-0"},{"key":"e_1_2_9_4_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction.European Drug Report 2022: Trends and Developments. Publications Office;2022. Accessed February 19 2023.doi:10.2810\/75644"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.07.026"},{"key":"e_1_2_9_6_1","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Reference Life Table. Published online2021.doi:10.6069\/1D4Y-YQ37"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2013.824328"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2004.08.012"},{"issue":"4","key":"e_1_2_9_9_1","first-page":"5","article-title":"Treatment of patients with substance use disorders, second edition. American Psychiatric Association","volume":"164","author":"Kleber HD","year":"2007","journal-title":"Am J Psychiatry"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.149.9.1212"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-199403000-00005"},{"key":"e_1_2_9_12_1","unstructured":"HAS. Prise en charge des consommateurs de coca\u00efne. Published online2010."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12081013"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2012.00248.x"},{"issue":"3","key":"e_1_2_9_15_1","first-page":"179","article-title":"Assessing craving for alcohol","volume":"23","author":"Drobes DJ","year":"1999","journal-title":"Alcohol Res Health"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4487(02)00212-3"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2012.670866"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0030992"},{"key":"e_1_2_9_19_1","unstructured":"JASP Team.JASP (Version 0.17) [Computer Software].;2023."},{"key":"e_1_2_9_20_1","unstructured":"R Core Team.R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing;2022."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.10.002"},{"key":"e_1_2_9_22_1","unstructured":"MarheR. Error\u2010Related Brain Activity Predicts Cocaine Use After Treatment at 3\u2010Month Follow\u2010up."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph182212259"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595230412331324518"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.2181"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.11.010"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2013.12065.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(96)01233-1"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.775670"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02519114"},{"key":"e_1_2_9_31_1","unstructured":"OFDT.La coca\u00efne un march\u00e9 en essor. \u00c9volutions et tendances en France (2000\u20102022). Published online2023."}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.13571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T08:11:57Z","timestamp":1725005517000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.13571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/ajad.13571"],"URL":"https:\/\/doi.org\/10.1111\/ajad.13571","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"2023-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}